Actions and Detail Panel
Informing global health decisions-Cost per DALY thresholds & health opp cos...
Wed 29 March 2017, 17:00 – 19:00 BST
Join us for a special guest lecture with Professor Karl Claxton, Centre for Health Economics, University of York.
This event is in partnership with our Global Health and Development Group
If you are an internal staff member or student from Imperial, you will be able to watch the event via live stream at this link here.
How can we be sure new investments in health are worth the money?
Evidence of the expected costs and health effects of an intervention are often summarised as cost per Disability Adjusted Life Year (DALY) ratios. These provide a useful summary of how much additional resource is required to achieve a measured improvement in health. Whether an effective intervention should be judged to be cost-effective because it will improve health outcomes overall requires a comparison with a ‘threshold’ that reflects the likely health opportunity costs.
Health opportunity costs are the amount of health that a HCS currently delivers with more or less resources. Estimates of the effect of different levels of health care expenditure on mortality can provide country specific cost per DALY averted values, taking account of measures of a country’s infrastructure, donor funding, population distribution, mortality rates, conditional life expectancies, estimates of disability burden and total health care expenditure.
In this lecture, Prof Claxton will present specific estimates of health opportunity costs for 123 counties, and will discuss how they might be improved and updated. He will also discuss how a range of global and national decisions can be better informed using measures of value based on estimates of health opportunity costs.
Karl Claxton is a Professor in the Department of Economics and the Centre for Health Economics at the University of York. He leads the economic evaluation component of the Health Economics MSc at the University of York. He is a past co-editor of the Journal of Health Economics and for many years held an adjunct appointment at the Harvard School of Public Health. His expertise spans economic evaluation, Bayesian decision theory and health policy and has authored textbooks on economic evaluation and decision modelling. He was a founding member of the NICE Technology Appraisal Committee and continues to contribute to the development of the NICE Guide to the Methods of Technology Appraisal. He also made a major contribution to the International Reference Case for Economic Evaluation as part of the International Decision Support Initiative. He continues to work in developing, communicating and implementing methods to better inform decisions in global health. He has contributed in a number of ways to recent policy debates such as pharmaceutical pricing and innovation. A well as NICE he has also advised, Department of Health, HM Treasury, Department of Business Innovation and Skills and the Office of Life Sciences.
International Decision Support Initiative (iDSI), a global network of health and economics expertise that supports countries to make better decisions to get the most from every dollar they spend on health care. The initiative is led by the Global Health and Development Group at Imperial College London.
Date and Time
Anthony de Rothschild Lecture Theatre, 2nd Floor, Medical School Building
St Mary’s Campus
London, England W2 1NY